{"version":"1.0","provider_name":"Merck.com","provider_url":"https:\/\/vip2-msd.com\/merckcom-migrated","author_name":"Merck.com","author_url":"https:\/\/vip2-msd.com\/merckcom-migrated","title":"Merck Resolves Vioxx\u00ae Litigation in Canada - Merck.com","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"9g5YNFhloU\"><a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-vioxx-litigation-in-canada\/\">Merck Resolves Vioxx\u00ae Litigation in Canada<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-resolves-vioxx-litigation-in-canada\/embed\/#?secret=9g5YNFhloU\" width=\"600\" height=\"338\" title=\"&#8220;Merck Resolves Vioxx\u00ae Litigation in Canada&#8221; &#8212; Merck.com\" data-secret=\"9g5YNFhloU\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/vip2-msd.com\/merckcom-migrated\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has entered into an agreement to resolve all claims related to Vioxx\u00ae in Canada. The agreement was signed by Merck and plaintiffs' representatives and is pending approval by courts in Canada's provinces. \"This agreement is structured to provide certainty and finality toward resolving Vioxx cases in Canada for a fixed amount,\" said Bruce N. Kuhlik, executive vice president and general counsel of Merck. \"Under the agreement, there will be an orderly, documented and objective process to examine individual claims to determine qualification.\" If the agreement is approved and specified conditions are met, Merck will pay a total amount of at least C$21,806,250 but not more than C$36,881,250. This would resolve all Vioxx certified class actions, putative class actions, other litigation and claims related to Vioxx in Canada. The amount to be funded for Vioxx users in Canada will be between C$11,306,250","thumbnail_url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20120517006246r1&sid=sfsite1&distro=nx"}